Quantitative CEST and MT at 1.5T for monitoring treatment response in glioblastoma: early and late tumor progression during chemoradiation.
Rachel W ChanHanbo ChenSten MyrehaugEshetu G AtenafuGreg J StaniszJames StewartPejman Jabehdar MaralaniAimee K M ChanShadi DaghighiMark RuschinSunit DasJames PerryGregory J CzarnotaArjun SahgalAngus Z LauPublished in: Journal of neuro-oncology (2020)
We observe the potential for multiparametric qMRI, including a novel pulsed CEST/MT approach, to show potential in distinguishing early from late progression GBM cohorts. Ultimately, the goal is to personalize therapeutic decisions and treatment adaptation based on non-invasive imaging-based biomarkers.